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Incorporating a clinical pharmacist in an outpatient palliative care team
Crystal Rim, PharmD; Sharon Leigh, PharmD, BCPS; Linda DeSitter, MD, MPH; Mary Grant, ANP

Background

Health & Services

Discussion

Methods

Findings

• The goals of palliative care are often different from the
traditional goals of medicine. Patients with limited life
expectancy unnecessarily have a large medication
burden, which may increase the risk of adverse drug
events due to side effects or drug-drug interactions.
• Several studies emphasize the need for medication deprescribing in a variety of palliative care populations.
• Fahlman et al identified 44% of community dwelling
elderly in their last year of life received at least one
inappropriate medication based on the Beers criteria.1
• Holmes et al developed a census that rated the
appropriateness of medications of 34 patients with
advanced dementia. Results showed that 29% of
patients were prescribed medication considered never
appropriate and 21% of patients were prescribed a
medication considered rarely appropriate.2
• Current studies demonstrating the integration of
pharmacists in the palliative care setting are limited.
• Whitman et al assessed pharmacists de-prescribing
interventions in older adults with cancer using three
geriatric screening tools (Beers Criteria, STOPP and MAI).
Results showed the pharmacists were able to identify
and de-prescribe 73% of potentially inappropriate
medications, with an average of 3 medications deprescribed per patient.3
• The evaluation of the clinical pharmacist and their
interventions may allow better care for palliative care
patients and improve interdisciplinary care within the
palliative care setting.

Telehealth

Telephone

• A telehealth visit is a video
consult conducted through
Zoom platform and is initiated
by the home health RN
• Nurse practitioners (NPs)
screen patients for study
eligibility as patients are
scheduled for outpatient
palliative care visits via
telehealth
• Clinical pharmacist reviews
chart prior to the visit and
identifies potentially
inappropriate medications and
optimizing medication
regimen
• Make recommendations to NP
via a 3-way telehealth call with
home health RN and NP
• NP passes on final
recommendations to the PCP

Consult
• NPs initiate and request
pharmacy consult on specific
patients to review current
medications and provide
assessment
• Pharmacist reviews chart
and/or interviews patient and
provides recommendations to
NP
• NP either accepts or denies
recommendations and sends
to PCP

Results
Recommendations Identified (n=64)
Medication Discontinuation, No.
PPI
8
Lipid-lowering agent
2
Anti-hypertensives
4
Antiplatelets
2
NSAIDs
2
Urogenital agents
1
CNS agents
2
Memantine
1
Supplements
5
Antibiotic
2
Medication optimization, No.
Therapy alternative
9
Dose adjustment
15
Administration
2
Therapy addition
4
Symptom management, No.
Pain
3
Bowel Regimen
1
Appetite stimulant
1

Baseline Characteristics

Labs on
admission:
Objectives

• The primary objective is to evaluate the clinical
pharmacist’s role within an outpatient palliative care
team performing medication reconciliation and review
and to potentially streamline the work involved in the
palliative care consult service. Medication review
includes de-prescribing high-risk medications and
optimizing medications in symptom management for
palliative care patients.

Study Design
• The study utilizes the STOPPFrail and Beers criteria as a
guide for de-prescribing potentially inappropriate
medication, optimizing medication use or adding
medication for symptom management. However, this
does not exempt clinical decision making that relies on
other patient factors.
• Study Period
• January 2020 to February 2020
• Study was followed up until March 2020
• Primary Endpoints
• Number of medications discontinued
• Number of recommendations accepted by
provider
• Number of medications recommended for
symptom management
• Time spent on chart/medication review
• Inclusion criteria
•
Adults at least 55 years of age
•
Enrolled in outpatient palliative care service
•
Have at least 5 routine medications at the time
of consult

• Clinical pharmacist screens
patients for study eligibility
• Prior to the scheduled home
visit with NP, pharmacist
initiates the interview to the
patient via telephone or
requests a medication
administration record (MAR)
to review current
medications
• Pharmacist sends
recommendations to NP at
least 2 days prior to the visit
• After the visit and in
consultation with NP,
pharmacist sends
recommendations to the
PCP

Demographics, N=19
Age, years, mean (range)
81 (63-95)
Sex, female, No. (%)
11 (58%)
Number of medications, average (range)
Total
15 (5-23)
Scheduled
11 (4-17)
PRN
3 (0-10)
Number of patients taking, No. (%)
Analgesic
15 (79%)
Opioid
4 (21%)
Non-opioid
11 (58%)
Long-term antibiotic
2 (11%)
Steroid
2 (11%)
Proton pump inhibitor (PPI)
11 (58%)
Lipid-lowering agent
11 (58%)
Ezetimibe
2 (11%)
Statin
9 (47%)
Anticoagulant
6 (32%)
Anticholinergics
3 (16%)
Aspirin
5 (26%)
Reason for Palliative Care Consult, No. (%)
Dementia
4 (21%)
Heart failure
4 (21%)

Recommendations Accepted (n=6)
Medications Discontinued
3
PPI
1
Supplement
2
Medication Optimized
3
Recommend antibiotic
Administration
Dose adjustment

1
1
1

Recommendations Identified (n=64)
Symptom Management

8%

Medication Optimization

47%

Medication Discontinuation

45%
0

Number of recommendations

5
10
Medication
Discontinuation
29

15
20
Medication
Optimization
30

25

30
35
Symptom
Management
5

• The majority of patients were taking an analgesic, PPI and
a lipid-lowering agent at baseline.
• Sixty eight percent of patients (n=13) were identified as
taking at least one medication that is considered
potentially inappropriate by STOPPFrail criteria.
• Clinical pharmacist was able to identify not only
medications for discontinuation but also medications for
optimization, which included adjusting the dose and
switching to a more suitable therapy alternative based on
safety or efficacy.
• While multiple methods of gathering data were used, the
most utilized method was telephone interviews (n=13),
followed by telehealth (n=4) and consult (n=2).
• A very small proportion of pharmacist recommendations
were accepted by the provider.
• The average time spent on chart review was 1.5 hours.

Study Limitations

• Non-randomized trial with a small sample size and lack of
control group for comparison
• Short duration of follow-up to track provider rejection or
acceptance of recommendations and safety outcomes
• Scheduled patient visits may be cancelled, postponed or
missed unexpectedly, which affected opportunities for
intervention.
• Because the pharmacist is not formally integrated into the
palliative care team, there was an educational component
to patients and providers about the pharmacist’s role.
• Changes to the pharmacist process (i.e. telehealth,
telephone and consult) were made throughout the study.
This may have led to inconsistent results as one method
may have been more effective than another.
• A large barrier to utilizing telehealth was the lack of
standardization of technology.
• The palliative care consult service makes
recommendations to providers and does not change active
medication orders. Since recommendations are written as
progress notes and may be either faxed or sent through
EMR message, there is limited certainty if the provider
received the recommendations in a timely manner.
• Many patients had various specialists managing their care,
which complicated sending recommendations to the most
appropriate provider.

Conclusions
• Pharmacist involvement in outpatient palliative care may be
valuable as evidenced by the number of interventions
identified by the clinical pharmacist.
• Many patients were taking medications, such as lipidlowering agents and PPIs, that may not be consistent with
their goals of care based on the STOPPFrail criteria and may
be subject to deprescribing.
• However, many barriers to providing meaningful
interventions were identified in this study.
• While telehealth potentially provided convenience to the
patient and caregivers, utilization by home health nurses
was limited due to lack of standardization of technology.
• Telephone interviews made by the clinical pharmacist
allowed proper medication reconciliation prior to the
palliative care visit, but non-medication related issues,
including hospice referrals, may be prioritized after the visit
by the NP and the provider.
• Pharmacy consult requested by palliative care nurse
practitioners allowed targeted efficiency, but it did not
allow formal pharmacist integration in the outpatient
palliative care team.
• Further studies quantifying the pharmacist’s role in
outpatient palliative care are warranted.
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